1. Home
  2. XAIR vs PFSA Comparison

XAIR vs PFSA Comparison

Compare XAIR & PFSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Beyond Air Inc.

XAIR

Beyond Air Inc.

HOLD

Current Price

$0.88

Market Cap

10.5M

Sector

Health Care

ML Signal

HOLD

PFSA

Profusa Inc.

N/A

Current Price

$0.09

Market Cap

9.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
XAIR
PFSA
Founded
2011
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.5M
9.1M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
XAIR
PFSA
Price
$0.88
$0.09
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$11.00
N/A
AVG Volume (30 Days)
144.0K
53.7M
Earning Date
02-09-2026
02-20-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$5,802,000.00
N/A
Revenue This Year
$128.45
N/A
Revenue Next Year
$153.25
N/A
P/E Ratio
N/A
N/A
Revenue Growth
147.74
122.22
52 Week Low
$0.67
$0.07
52 Week High
$10.40
$12.76

Technical Indicators

Market Signals
Indicator
XAIR
PFSA
Relative Strength Index (RSI) 43.15 N/A
Support Level $0.78 N/A
Resistance Level $0.98 N/A
Average True Range (ATR) 0.07 0.00
MACD 0.04 0.00
Stochastic Oscillator 69.06 0.00

Price Performance

Historical Comparison
XAIR
PFSA

About XAIR Beyond Air Inc.

Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.

About PFSA Profusa Inc.

Profusa Inc is a clinical-stage digital health and medical technology company focused on developing biosensing solutions to improve health outcomes for patients with a variety of different diseases and conditions. The Company's technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. The Company's first offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term.

Share on Social Networks: